Gland Pharma Ltd Board Meeting Scheduled for May 15, 2026; Final Results and Dividend to be Reviewed
Gland Pharma Ltd is scheduled to hold a meeting of its Board of Directors on Friday, May 15, 2026. The meeting will focus on approving the company's financial performance and recommending the payment of the final dividend.During the Board meeting, directors will consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and the full financial year ended March 31, 2026. A key item on the agenda is the review and recommendation for the payment of the Final Dividend for the financial year 2025-26.
The company has also announced an Investor/Analyst call, scheduled for Friday, May 15, 2026, at 18:30 Hrs (IST). Further operational details regarding the call will be published on the company's official website.
In relation to market trading activities, the trading window, which had been closed from Saturday, March 28, 2026, will reopen on Monday, May 18, 2026.
For quick reference, the key corporate dates are summarized below:
| Event | Date | Time (IST) |
|---|---|---|
| Board Meeting | Friday, May 15, 2026 | N/A |
| Investor/Analyst Call | Friday, May 15, 2026 | 18:30 Hrs |
| Trading Window Reopens | Monday, May 18, 2026 | N/A |
The company confirmed that the Board meeting agenda specifically includes the consideration of the audited financial results and the recommendation of the final dividend for FY 2025-26.
GLAND Stock Price Movement
Shares of Gland Pharma Limited today slipped by 0.79% to close at ₹1781, shedding ₹14.20 in post-market trading. The equity saw a trading volume of 110,104 shares, completing its day's movement between a low of ₹1761.6 and a high of ₹1792.8.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.